Assembly Biosciences to present hepatitis delta drug data at EASL congress
Assembly Biosciences Inc. (NASDAQ: ASMB) will present topline Phase 1a clinical data for ABI-6250, an oral hepatitis D virus entry ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
